Insomnia

StrainsForPains, Inc. Discusses Inspiration, App Technology and CBD Market Entrance with The Stock Day Podcast

Retrieved on: 
Thursday, February 29, 2024

I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.

Key Points: 
  • I financed and worked with Olivia Newton-John's Koala Blue in the 1980's and Richard Diehl's Graphsoft (now Vectorworks) in the 1990's.
  • I developed regenerative medicine systems with stem cell technology in the 1980's working on umbilical cord therapy to treat genetic diseases, cancers, and inherited disorders.
  • In 2024 we will focus our efforts on the development of our upcoming advanced AI app and our CBD brand that will expand into many products.
  • We will seek to forge a new path in our approach to healthcare, that will expand to CBD products for pets as well as a nutritional app.

HIMALAYA TECHNOLOGIES PARTNERS WITH RENOVI! TO TARGET MEDICAL TOURISM MARKET IN CARIBBEAN; ADDS CEO TO ADVISORY BOARD

Retrieved on: 
Monday, March 11, 2024

Additionally, the Company has appointed Renovi!’s CEO, David Burns, Ph.D., to its Advisory Board to guide its entry into this multi-billion dollar market, assist on mergers and acquisitions including a potential combination of Renovi!

Key Points: 
  • Additionally, the Company has appointed Renovi!’s CEO, David Burns, Ph.D., to its Advisory Board to guide its entry into this multi-billion dollar market, assist on mergers and acquisitions including a potential combination of Renovi!
  • The availability of the newest medical technologies and the cheaper cost of treatment in emerging nations are key market drivers enhancing market growth.
  • reinvents traditional outpatient rehabilitation by offering patients a “recovery vacation” at an upscale, beachfront medical resort with healthy diet, exercise, community and exceptional medical care.
  • The Dominican Republic is uniquely positioned as a medical tourism destination because of its low costs, proximity to the U.S., a well-established tourism infrastructure, and tax incentives for tourism investments.

Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia

Retrieved on: 
Monday, March 11, 2024

CHATHAM, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the presentation of additional efficacy data from RESILIENT, the second positive Phase 3 study evaluating Tonmya (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, at the 6th International Congress on Controversies in Fibromyalgia in Brussels, Belgium, March 7-8, 2024.

Key Points: 
  • We now report that the effect sizes of the five continuous key secondary outcomes measures ranged from 0.3 to 0.5.
  • The FIQ-R cognitive item showed nominal improvement in Tonmya-treated patients vs placebo-treated patients with a p=0.001 and effect size of 0.31.
  • RELIEF, the first Phase 3 trial of Tonmya 5.6 mg in fibromyalgia, was completed in December 2020.
  • We also believe the favorable tolerability and side effect profiles will be important to patients and doctors managing this debilitating condition on a long-term basis.”

New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT

Retrieved on: 
Thursday, March 7, 2024

First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.

Key Points: 
  • First, in October 2023, veterinarians presented SPRYNG™'s positive study results on dogs with cranial cruciate ligament (CCL) disease.
  • Also, Ethos Veterinary Health, LLC's study on canine hip dysplasia using the product shows success, giving more veterinary doctors information about product uses.
  • PETV's SPRYNG™ with OsteoCushion Technology is a "Game Changer" medical device that successfully treats pets and gives owners options beyond surgeries.
  • New to The Street airs TV Host Jane King's interview with VRM BioLogik® Group's (VRM) Ken Bellamy, Founder and President .

Nexalin Technology Announces Positive Results from Clinical Study of its Gen-2 tACS Device for Treating Adult Patients with Chronic Insomnia

Retrieved on: 
Wednesday, March 6, 2024

HOUSTON, TEXAS, March 06, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced positive results of a clinical study of its Gen-2 tACS device (“tACS”) for the treatment of chronic insomnia. This clinical study, conducted at Xuanwu Hospital of Capital Medical University in Beijing and Beijing Anding Hospital, evaluated the treatment response of 120 adult participants who were divided into two prespecified age subgroups.

Key Points: 
  • Key data reported from the study suggests that tACS ameliorates chronic insomnia, and that age can impact the extent of the resulting improvement from tACS treatment.
  • Older participants (ages 50 and over) experienced comparatively more significant benefits from tACS, in terms of enhanced sleep quality, efficiency and overall insomnia reduction (p
  • This is attributed to the natural changes in sleep physiology that occur with aging and the distinct manifestations of insomnia symptoms in older individuals.
  • The clinical study’s results, which were published in the Journal of Psychiatric Research, showed that tACS meaningfully reduced the severity of insomnia and enhanced sleep quality and efficiency.

Herbal medicinal product: Lupuli flosArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of hop strobile.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing hop strobile.
  • Herbal medicines containing these hop strobile preparations are usually available as herbal tea to be drunk or in liquid or solid forms to be taken by mouth.
  • Hop strobile preparations may also be found in combination with other herbal substances in some herbal medicines.

Herbal medicinal product: Avenae herbaArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of oat herb.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing oat herb.
  • Herbal medicines containing these oat herb preparations are usually available in solid or liquid forms to be taken by mouth or as herbal tea to be drunk.
  • Oat herb preparations may also be found in combination with other herbal substances in some herbal medicines.

StimScience Hires Former Fitbit Executive Tim Rosa as Chief Executive Officer to Scale its Somnee Sleep and Neuroscience Wearable Business

Retrieved on: 
Wednesday, March 6, 2024

Somnee – the first personalized, smart sleep headband that utilizes non-invasive, closed-loop neurostimulation for longer, higher quality sleep – today announced the appointment of Tim Rosa as its Chief Executive Officer (CEO).

Key Points: 
  • Somnee – the first personalized, smart sleep headband that utilizes non-invasive, closed-loop neurostimulation for longer, higher quality sleep – today announced the appointment of Tim Rosa as its Chief Executive Officer (CEO).
  • “Wearables have done a great job educating consumers on their general sleep stage trends and insights.
  • We backed Somnee because the team had every component needed to bring forward clinical-grade consumer technology to change the face of sleep.
  • As the former Chief Marketing Officer (CMO) at Fitbit, he was pivotal in establishing the connected health and fitness wearables category.

RedBox Rx Releases New Study That Finds Nearly 3 Out of 4 Americans Struggled with Mental Health

Retrieved on: 
Tuesday, February 20, 2024

The study was commissioned by RedBox Rx, a telehealth and online pharmacy provider that specializes in mental health treatment, and conducted by Morning Consult, a global intelligence company.

Key Points: 
  • The study was commissioned by RedBox Rx, a telehealth and online pharmacy provider that specializes in mental health treatment, and conducted by Morning Consult, a global intelligence company.
  • “Mental health remains a struggle for many Americans,” said Dr. Daniel Fick, RedBox Rx’s chief medical officer.
  • Those suffering from worsening mental health were more likely to have experienced the following:
    The study also indicated that mental health challenges varied among age groups.
  • RedBox Rx offers treatment plans for men’s health , women’s health , hair and skin , mental health , allergies and more.

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Retrieved on: 
Wednesday, March 6, 2024

In July 2023, the FDA had assigned a Prescription Drug User Fee Act target date of March 4, 2024 for the completion of its review of the sNDA.

Key Points: 
  • In July 2023, the FDA had assigned a Prescription Drug User Fee Act target date of March 4, 2024 for the completion of its review of the sNDA.
  • As previously reported, on February 4, 2024, the FDA provided a notification stating that it identified deficiencies that precluded discussion of labeling and postmarketing requirements/commitments.
  • Consistent with that notification, the FDA has issued a CRL, indicating that the FDA cannot approve the sNDA in its present form.
  • Vanda is reviewing the CRL and evaluating its next steps.